MOLN News

Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling

Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712

Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting

Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors

Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins’ Amenability to Multiple Isotopes

Molecular Partners to Hold Three Poster Presentations at AACR 2026

Molecular Partners Reports Highlights and Financial Results for Full Year 2025

Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results

Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics

Anti-Biofilm Agents Market to Worth Over USD 4.32 Billion By 2035 | Escalating Hospital Infection Rates Drive Urgent Clinical Agent Adoption and Market Growth says Astute Analytica